Vinn,
Excellent post and what a progressive coy to be partnership with.
TEVA's no 1 selling drug is its $3 billion multiple sclerosis(MS) drug Copaxone which currently makes up 21% of sales(coming off patent in 2013). So TEVAs acquisition of CEPH now has the merged entity @ $20bn - talk about forward planning by this super Global Pharma.
And if the Cardio Franshise wanst enough, just to make sure that MSB retains its NO 1 'sweetheart' title within the TEVA family, the Blaster is looking at developing an MS application as part of its Intravenous Program /Francshise ( page 5 annual report).
Great 2012 coming on !
Cheers to all holders.
this company is now a substantial holder ...., page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
-0.010(1.08%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 94.0¢ | 91.5¢ | $1.609M | 1.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 131951 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |